OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Jänne on Osimertinib Plus Platinum-Based Chemotherapy in EGFR-Mutant NSCLC

September 11th 2023

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS

September 9th 2023

Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.

Dr Erba on the Role of Quizartinib in Newly Diagnosed FLT3-ITD+ AML

September 9th 2023

Harry Erba, MD, PhD, discusses the role of quizartinib for the treatment of newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Mead on Unanswered Questions in the Treatment of MCL

September 8th 2023

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma

September 8th 2023

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

September 8th 2023

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC

September 8th 2023

Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.

Dr. Li on the Potential For First-Line Triplet Therapy in HCC

September 8th 2023

Daneng Li, MD, discusses the investigation of triplet combination therapy for patients with hepatocellular carcinoma in the phase 1/2 Morpheus-Liver study.

Dr Hamilton on the Benefit Derived From Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 8th 2023

Erika P. Hamilton, MD, discusses the benefit seen with adjuvant ribociclib in patients with hormone receptor-positive,HER2-negative breast cancer.

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Dr Birrer on Molecular Stratification in Endometrial Cancer

September 8th 2023

Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.

Dr Myall on Immunotherapy Doublets and Chemoimmunotherapy in NSCLC

September 8th 2023

Nathaniel Myall, MD, clinical assistant professor, medicine - oncology, Stanford Medicine, discusses efficacy findings from 3 clinical trials investigating combination immunotherapy and chemoimmunotherapy treatment approaches in patients with non–small cell lung cancer.

Dr Deol on Sequencing Treatment Options With CAR T-Cell Therapy in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Dr Barzi on Unmet Needs in the Adjuvant Treatment of Gastroesophageal Cancers

September 7th 2023

Afsaneh Barzi, MD, PhD, discusses unmet needs associated with the adjuvant treatment of patients with gastroesophageal cancers and highlights the use of nivolumab in this setting.

Dr Pothuri on the Promise of the RUBY and NRG-GY018 Trials in Endometrial Cancer

September 7th 2023

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

September 7th 2023

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1

September 7th 2023

Yi Lin, MD, PhD, the predictive value of baseline characteristics in relation to sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Schneider on Targeted Treatment Options in MET Exon 14 Mutated–NSCLC

September 7th 2023

Bryan Schneider, MD, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer.

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

September 7th 2023

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL

September 7th 2023

Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.